Did you know that you can order an eco-conscious burger in Houston? Photo courtesy of Hopdoddy

Hearty Austin-based chain Hopdoddy Burger Bar has unveiled a new lineup of regenerative burgers that are supposed to be better for the planet and the consumer.

The term "regenerative burger" could cause a few head-scratches: Some may think of lab-grown or 3D-printed meat, while others think of plant-based alternatives but it’s neither. It is grass-fed meat, sourced a bit differently. "Regenerative farming" is a term used to describe farming and grazing practices that claim to restore and rebuild degraded soil, resulting in better-quality air and water.

Hopdoddy’s vice president of culinary Matt Schweitzer explained that it all began with with a sense of obligation to do better as a brand for the consumers and the ecosystem.

“We felt like we could really take a stand and look to move our entire supply chain in a regenerative fashion, so we could really be proud of the work we’ve done and we could hopefully leave the animals, the farmers, the ranchers, the native grasslands, and our planet a better place than before we started,” says Schweitzer.

The new menu items include the "Roosevelt Burger" with grass-fed regenerative bison; the "Nashville Hot Sandwich" with regenerative raised chicken; the "Regenerative Royale," which is a play on a classic double quarter-pounder with cheese; the "Mother Nature" with grass-fed regenerative beef; and the "Buffalo Bill" also uses regenerative bison, but appears not to be grass-fed.

The five burgers are available at all Hopdoddy locations nationwide. The beef and bison are sourced from Texas-based regenerative company Force of Nature, while the chicken is from Cooks Venture.

With this launch, Hopdoddy removes all plant-based meat substitutes from its menu, significantly reducing the options for vegans and vegetarians. The company felt the ingredients and ethos of the alternative meats — describing some such as Beyond Meats as "falsely advertised" regarding nutrition in a press release — no longer aligned with its values and mission. However, the house-made veggie patty remains on the signature "El Bandito" burger.

Schweitzer says the regenerative burgers have received positive feedback, as people are excited to know where their food comes from, how it gets to their table, and what type of impact it causes. Regarding the future of regenerative meat, he says there is no doubt it could become mainstream soon.

“I think the flavor profile, the eating experience, the story, the mission, the purpose, really speaks for itself," says Schweitzer. "So, I really think it’s a matter of time until 'regenerative' is talked about in the same way that 'organic,' or 'sustainable,' or those type of buzzwords are talked about."

To further show its commitment to regenerative agriculture, Hopdoddy is also one of the sponsors of Common Ground, a documentary about the pioneers of the regenerative movement, premiering October 4 in Austin. The "uplifting" film, according to a release, features well-known actors Laura Dern, Rosario Dawson, Jason Momoa, Woody Harrelson, Ian Somerhalder, and Donald Glover, emphasizing that this motley crew does share one thing in common: a strong belief in regenerative agriculture.

For more information about the new regenerative burgers, visit hopdoddy.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.